The Increasing Incidence of Prostate Cancer

Prostate cancer is the most common cancer in men and the second leading cause of death amongst men in the United States. It’s estimated that about 1 in 7 men will be diagnosed with prostate cancer during their lifetime. Men between the ages of 60 and 69 are most at risk, with more than 65% of those diagnosed being over the age of 65. Approximately 1 in 36 men affected by prostate cancer will die from it. In addition to age, other primary risk factors for this specific type of cancer include race, family history/genetics, diet, and lifestyle choices.

Regular screenings can go a long way to ensure that your prostate is healthy and functioning properly. Screenings may include a physical exam of the gland by your doctor, as well as a test to determine your Prostate-Specific Antigens levels. Since both healthy and malignant cells in your prostate gland produce PSAs, these levels are measured to determine abnormalities. PSA levels higher than 4.0 nanograms per milliliter of blood are generally considered atypical and may warrant further tests.

Although, more recently, PSA as low as 2.5 are being considered a concern for suspicion. In addition, there is a new prostate cancer detection test known as 4-k score that is proven extremely sensitive for early detection of prostate cancer.

Quick Facts:

Second to skin cancer, prostate cancer is the most common kind of cancer affecting American men.

African-American men and Caribbean natives experience the highest incidences of prostate cancer.

Men who have a relative with prostate cancer are twice as likely to develop the disease as men who don’t. The definition of relatives includes any and all males within a family.

Men with two or more relatives with the diseases are about four times as likely to be diagnosed with it as those who don’t. (The risk is substantially higher if the affected relatives were diagnosed with the disease prior to age 65.)

A strong family history of other cancers (i.e.: breast, colon, or ovarian cancer) may also increase your risk of developing prostate cancer.

While older men are more likely to be diagnosed with the disease, early detection is an important part of prevention and treatment. The sooner cancerous cells are found, the sooner they can be treated in order to stop stopped from metastasizing, or spreading throughout the rest of your body.

Whether metastatic or not, prostate cancer can wreak havoc on the body. However, localized prostate cancer has grown much easier to treat. In fact, Dr. George Suarez, a Miami based urologist is the founder of Sonacare Medical, the world’s leader in HIFU technology to treat prostate cancer. As medical director of the company’s FDA clinical trials, they received FDA approval in October 2015. to date he has performed over 3,00 HIFU cases recently joined several cities around the world in providing high intensity focus ultrasound (HIFU) is a new, noninvasive, and/or radiation surgical option to patients with localized prostate cancer. Likewise, HIFU can be used in men that have radiation recurrence, as opposed to being placed on hormone therapy and being subjected to the toxic side effects of such treatment. This treatment is known as high-intensity focused ultrasound (or the HIFU procedure). HIFU technology works by using high-intensity sound waves to focus in on a single section of your prostate, rather than the entire gland. The sounds waves can then target the tumor(s) in this specified region through an ultrasound probe. Your surgeon controls this probe via a robotic arm that only moves in millimeters to reduce pain and discomfort.